JasmineZainMD

PubMed

• A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
  Muhamad Alhaj Moustafa, Jeremy L Ramdial, Athanasios Tsalatsanis, Farhad Khimani, Bhagirathbhai Dholaria, Leyla Bojanini, Taylor Brooks, Jasmine Zain, N Nora Bennani, ...> ;Transplantation and Cellular Therapy. 2024 Feb 29
• Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
  Ong, S., Zain, J.> ;American Journal of Hematology. 2024 Mar 1
• Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
  Chen, L., Rosen, S., Zain, J., Querfeld, C., Trum, N.> ;The British Journal of Dermatology. 2024 Jan 29
• Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.
  Davila, E., Bradeen, X., Abbott, D., Zain, J., Kamdar, M., Neuwelt, A., Jasem, J., Porcu, P., Major, A., Major, A., Haverkos, B., Major, A., Bair, S., Smith, C.> ;Blood Advances. 2024 Feb 13
• 5 citations
  Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-c...
  Shin Yeu Ong, Stacy Pak, Matthew Mei, Yan Wang, Leslie Popplewell, John H Baird, Alex F Herrera, Geoffrey Shouse, Liana Nikolaenko, Jasmine Zain, James Godfrey, Myo Ht...> ;American Journal of Hematology. 2023 Nov 1
• 2 citations
  Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
  Zhen Han, Xiwei Wu, Hanjun Qin, Yate-Ching Yuan, Daniel Schmolze, Chingyu Su, Jasmine Zain, Lilach Moyal, Emmilia Hodak, James F Sanchez, Peter P Lee, Mingye Feng, Ste...> ;JCI Insight. 2023 Jul 10
• 7 citations
  Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
  Matthew Mei, Lu Chen, James Godfrey, Joo Song, Colt Egelston, Sandrine Puverel, L Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Mary Nwangwu, Weihua Guo, Lei Gao, ...> ;Blood. 2023 Oct 19
• 4 citations
  Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
  Jia Ruan, Jasmine Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N Winter, Leo I Gordon, Reem Karmali, Jonathan Moreira, Adam M Petrich, Barbara Pro> ;Blood Advances. 2023 Oct 10
• 2 citations
  A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
  Mwanasha H Merrill, Parastoo B Dahi, Robert A Redd, Mikaela M McDonough, Yi-Bin Chen, Zachariah DeFilipp, Alex F Herrera, David C Fisher, Ann S LaCasce, Oreofe O Odeji...> ;Blood. 2023 Aug 17
• 1 citations
  Integrative Oncology and the Clinical Care Network: Challenges and Opportunities.
  George Semeniuk, Bahareh Bahadini, Eugene Ahn, Jasmine Zain, Jessica Cheng, Ameish Govindarajan, Judy Rose, Richard T Lee> ;Journal of Clinical Medicine. 2023 Jun 9
• 3 citations
  Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
  Robert Stuver, Steven M Horwitz, Ranjana H Advani, Julie M Vose, Hun Ju Lee, Neha Mehta-Shah, Jasmine M Zain, Bradley Haverkos, Mary Jo Lechowicz, Alison J Moskowitz, ...> ;British Journal of Haematology. 2023 Aug 1
• 1 citations
  Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy.
  Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F ...> ;Journal of the National Comprehensive Cancer Network. 2023 Apr 1
• 2 citations
  Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
  Zhen Han, Xiwei Wu, Hanjun Qin, Yate-Ching Yuan, Jasmine Zain, D Lynne Smith, Oleg E Akilov, Steven T Rosen, Mingye Feng, Christiane Querfeld> ;The Journal of Investigative Dermatology. 2023 Aug 1
• 2 citations
  Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell L...
  Julio C Chavez, Francine M Foss, Basem M William, Jonathan E Brammer, Sonali M Smith, Anca Prica, Jasmine M Zain, Joseph M Tuscano, Harsh Shah, Neha Mehta-Shah, Pravee...> ;Clinical Cancer Research. 2023 May 15
• 1 citations
  Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma.
  George Glinos, Grace Wei, Jacob Nosewicz, Farah Abdulla, Pei-Ling Chen, Catherine Chung, Benjamin H Kaffenberger, Christiane Querfeld, Michi M Shinohara, Lubomir Sokol...> ;JAMA Dermatology. 2023 Feb 1
• 2 citations
  Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
  Furqan, F., Ahn, K., Chen, Y., Kaur, M., Abutalib, S., Ahmed, N., Ahmed, S., Kharfan-Dabaja, M., Friedberg, J., Gregory, T., Hill, L., Sterling, C., Barta, S., Shadman...> ;British Journal of Haematology. 2023 Jan 1
• 3 citations
  Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability.
  Jasmine Zain, Avyakta Kallam> ;Frontiers in Oncology. 2023 Jan 1
• 1 citations
  Circulating Tumor DNA in Lymphoma.
  Swetha Kambhampati, Jasmine Zain> ;Current Hematologic Malignancy Reports. 2022 Dec 1
• 15 citations
  Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
  Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G Mei, Leslie L Popplewell, Tanya Siddiqi, Jasmi...> ;Blood. 2022 Nov 10
• 6 citations
  Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary synd...
  Cosimo Di Raimondo, Belen Rubio-Gonzalez, Joycelynne Palmer, Dennis D Weisenburger, Jasmine Zain, Xiwei Wu, Zhen Han, Steven T Rosen, Joo Y Song, Christiane Querfeld> ;The British Journal of Dermatology. 2022 Aug 1
• 12 citations
  Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
  Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G Mei, Tanya Siddiqi, Leslie L Popplewell, Yi-Ping Wen, Jasmine Zain,...> ;Blood. 2022 Dec 22
• 3 citations
  Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy.
  Jana K Dickter, Justine A Ross, Jasmine M Zain, Bernard R Tegtmeier, Brian V Lee, Sanjeet S Dadwal> ;Journal of Clinical Pharmacy and Therapeutics. 2022 May 1
• 35 citations
  Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
  Matthew G Mei, Hun Ju Lee, Joycelynne M Palmer, Robert Chen, Ni-Chun Tsai, Lu Chen, Kathryn McBride, D Lynne Smith, Ivana Melgar, Joo Y Song, Kimberley-Jane Bonjoc, Sa...> ;Blood. 2022 Jun 23
• 46 citations
  T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
  Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, Jeffrey Barnes, Stefan K Barta, Jonathan Brammer, Mark W Clemens, Ahmet Dogan, Francine Foss, Paola Ghione, Aaron M Good...> ;Journal of the National Comprehensive Cancer Network. 2022 Mar 1
• 2 citations
  Emerging drugs for the treatment of cutaneous T-cell lymphoma.
  Melissa Cheng, Jasmine Zain, Steven T Rosen, Christiane Querfeld> ;Expert Opinion on Emerging Drugs. 2022 Mar 1
• Join now to see all

Abstracts/Posters

• Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
  Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
  Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
  Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
  Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
  Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
  Jasmine M. Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression an...
  Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• 6th Annual Conference On How The Experts Treat Hematologic Malignancies 
  City of Hope, Santa Monica, California - 9/18/2013